Published on Roswell Park Cancer Institute (http://www.roswellpark.org)

Chief, Leukemia Section, Department of Medicine
Professor of Medicine, Department of Medicine
Roswell Park Cancer Institute
Professor of Medicine
School of Medicine and Biomedical Sciences, State University of New York at Buffalo
Profile
Areas of Expertise: 
Hematologic Oncology
Acute lymphoblastic leukemia (ALL)
Acute myeloid leukemia (AML)
Chronic myeloid leukemia (CML)
Myelodysplastic syndrome (MDS)
Myeloproliferative diseases (MPD)
Research
Research Interests: 
Role of signal transducer and activator of transcription in leukemogenesis
Cellular and humoral immune response to leukemic-associated antigens
Cytogenetics in AML and ALL
Selected Publications: 

Background Information
Education and Training: 
MD - Hebrew University, Hadassah Medical School, Jerusalem, Israel
Residency: 
Kaplan Hospital, Hebrew University, Hadassah Medical School, Rehovot, Israel
Board Certification: 
Internal Medicine, American Board of Internal Medicine
Medical Oncology, American Board of Internal Medicine
Fellowships: 
University of Texas, MD Anderson Cancer Center, Houston, TX
Publications
Publications: 
  • Becker H, Larson RA, Caligiuri MA, Baer MR, Carroll AJ, Wetzler M, Kolitz JE, Carter TH, Powell BL, Paschka P, Schwind S, Wu Y-Z, Whitman SP, Margeson D, Mrozek K, Radmacher MD, Maharry K, Marcucci G, Bloomfield CD. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. Journal of clinical oncology 2010; 28(4):596-604
  • Faderl S, O'Brien S, Pui C-H, Stock W, Wetzler M, Hoelzer D, Kantarjian HM. Adult acute lymphoblastic leukemia: concepts and strategies. Cancer 2010; 116(5):1165-1176
  • Francis J, Spangenthal E, Cohen IL, McCarthy PL, Smiley S, Paplham P, Wang E, Wetzler M, Ahluwalia MS, Battiwalla M. Reversible cardiotoxicity with tyrosine kinase inhibitors. Clinical advances in hematology and oncology : H&O 2010; 8(2):128-132
  • Marcucci G, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Metzeler KH, Schwind S, Maharry K, Wu YZ, Radmacher MD, Mrozek K, Margeson D, Holland KB, Whitman SP, Becker H, Bloomfield CD. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Journal of clinical oncology 2010; 28(14):2348-2355
  • Ngamphaiboon N, Sweeney R, Wetzler M, Wang ES. Pyridoxine treatment of vincristine-induced cranial polyneuropathy in an adult patient with acute lymphocytic leukemia: Case report and review of the literature. Leukemia research 2010; 34(8):e194-6
  • Nowak NJ, Wang ES, Wallace PK, Ford L, Liu S, Gaile D, Deeb G, Zeidan A, Sait SNJ, Wetzler M. Recurrent deletion of 9q34 in adult normal karyotype precursor B-cell acute lymphoblastic leukemia. Cancer genetics and cytogenetics 2010; 199(1):15-20
  • Becker H, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Moore JO, Caligiuri MA, Larson RA, Powell BL, Wu Y-Z, Schwind S, Marcucci G, Maharry K, Radmacher MD, Mrozek K, Margeson D, Whitman SP, Paschka P, Holland KB, Bloomfield CD. Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 2010; 116(5):788-792
  • Becker H, Carter T, Kolitz J, Wetzler M, Carroll A, Baer M, Moore J, Caligiuri M, Larson R, Powell B, Metzeler K, Schwind S, Marcucci G, Maharry K, Radmacher M, Wu Y, Mrozek K, Whitman S, Margeson D, Holland K, Bloomfield C. CEBPA double mutations impact favorably on the outcome of older adults with wild-type NPM1 cytogenetically normal acute myeloid leukemia and are associated with distinct gene and microRNA expression. Haematologica 2010; 95(Suppl. 2):Abstract #593
  • Cortes J, Laadem A, Brown Jr A, Krishnamurthy M, Abboud CN, Pham D, Schiller GJ, Dey BR, Luger S, Matous J, Craig M, Wetzler M, Maziarz RT, Moore JO, Seiter K. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study. Journal of clinical oncology 2010; 28(27):4207-4213
  • Ghoshal S, Rao I, Earp JC, Jusko WJ, Wetzler M. Down-regulation of heat shock protein 70 improves arsenic trioxide and 17-DMAG effects on constitutive signal transducer and activator of transcription 3 activity. Cancer chemotherapy and pharmacology 2010; 66(4):681-689
  • Hampras SS, Ford L, Blanco JG, Chennamaneni R, Wetzler M, Singh PK, Zirpoli G, Baer MR, Weiss J, Sucheston L, Moysich KB. Genetic polymorphisms of ATP-binding cassette (ABC) proteins, overall survival and drug toxicity in patients with acute myeloid leukemia. International journal of molecular epidemiology and genetics 2010; 1(3):201-207
  • Klisovic B, Chan K, Murray P, Solomon S, Grosskreutz C, Damon L, Sayar H, Wetzler M, Byrd J, Garzon R, Devine S, Walker A, Liu S, Xie Z, Chen P, Blum W, Marcucci G. A phase II study of GTI-2040, an antisense to ribonucleotide reductase in combination with high-dose cytarabine in relapsed or refractory acute myeloid leukemia. Haematologica 2010; 95(Suppl. 2):Abstract #66
  • Kuptsova-Clarkson N, Wetzler M, Blanco J, Ford L, Kopecky KJ, Zirpoli G, Sucheston LE, Baer MR, Weiss J, Ambrosone CB, Moysich KB. XPD DNA nucleotide excision repair gene polymorphisms associated with DNA repair deficiency predict better treatment outcomes in secondary acute myeloid leukemia. International journal of molecular epidemiology and genetics 2010; 1(4):278-294
  • Link PA, Zhang Wa, Gold D, Wetzler M, Baer MR, Karpf AR. p53 target gene expression, DNA hypomethylation, and clinical response in MDS patients undergoing decitabine therapy. Proceedings of the American Association for Cancer Research Annual Meeting 2010; 51:47-48
  • Varadarajan R, Cummings MK, Hyland AJ, Wang ES, Wetzler M. Can decreasing smoking prevalence reduce leukemia mortality?. Annals of hematology 2010; 89(9):873-876
  • , Nowak NJ, Wetzler M, Ford LA, Starostik P, Mashtare T, Gold D, Sait SNJ, Wang ES, Deeb G. Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapse. Cancer genetics and cytogenetics 2010; 202(2):101-107
  • Wetzler M, Wang E, Thompson J, Baer M, Block AM, Sait S, Barcos M, Tighe S, Ford LA, Andrews C, Baumann H. Priming with arsenic trioxide improves the outcome of newly diagnosed acute myeloid leukemia patients < 60 years old treated with high-dose cytarabine and idarubicin. Haematologica 2010; 95(Suppl. 2):Abstract #64
  • Pailler M, Johnson TM, Wang ES, Wetzler M. Marital satisfaction, social support and distress among patients with acute leukemia and their caregivers: a longitudinal study. Annals of behavioral medicine 2010; 39(Suppl. 1):73
  • Marcucci G, Powell B, Carter T, Kolitz J, Wetzler M, Baer M, Carroll A, Caligiuri M, Larson R, Metzeler K, Schwind S, Maharry K, Wu YZ, Radmacher M, Mrozek K, Margeson D, Holland K, Whitman S, Becker H, Bloomfield C. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) study. Haematologica 2010; 95(Suppl. 2):Abstract #1107
  • Lal D , Fetterly GJ , Wetzler M , Prey J , Murphy M , Mashtare TJ , Tian L , Lin M-H , Perez AM , Marinaro J , Demock K , Park JA , Wang ES. Aflibercept exerts antivascular effects and enhances levels of anthracycline chemotherapy in vivo in human acute myeloid leukemia models. Molecular cancer therapeutics 2010; 9(10):2737-2751
  • Whitman SP , Carter TH , Kolitz JE , Wetzler M , Moore JO , Stone RM , Carroll AJ , Larson RA , Caligiuri MA , Marcucci G , Powell BL , Baer MR , Wen J , Maharry K , Radmacher MD , Becker H , Mrozek K , Margeson D , Holland KB , Wu Y-Z , Schwind S , Metzeler KH , Bloomfield CD . FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 2010; 116(18):3622-3626
  • Brady MT, Lee J, Ferrone S, Wang ES, Wetzler M. Interferon-gamma secretion by t(9;22) acute lymphoblastic leukemia-derived dendritic cells. Leukemia research 2011; 35(2):275-277
  • Blum W, Moser BK, Hoke E, Wetzler M, Kolitz JE, Baer M, Stock W, Powell BL, Uy GL, DeAngelo DJ, Marcucci G, Donohue K, Larson RA. Challenges for conducting clinical trials evaluating maintenance chemotherapy in acute myeloid leukemia (AML): A cancer and leukemia group B (CALGB) study. Blood 2010; 116(21):2176
  • Brady MT, Miller A, Sait S, Ford LA, Hans M, Wang ES, Lee KP, Baumann H, Wetzler M. Down-regulation of signal transducer and activator of transcription 3 enhances acute myeloid leukemia-derived dendritic cell function. Blood 2010; 116(21):3140
  • Cortes JE, Craig A, Benichou A, Humphriss ED, Cram D, Khoury HJ, Baer MR, Baccarani M, Nicolini FE, Lipton J, Wetzler M, Kantarjian HM. Subcutaneous omacetaxine (OM) treatment of chronic phase (CP) chronic myeloid leukemia (CML) patients following multiple tyrosine kinase inhibitor (TKI) failure. Blood 2010; 116(21):2290
  • Garcia-Manero G, Chiao J, Goldberg SL, Foran JM, JR, Strickland SA, Claxton DF, Altman JK, Wetzler M, Maness L, Venugopal P, Luger S, Kantarjian HM. A randomized phase 2 study of sapacitabine, an oral nucleoside analogue, in older patients with MDS refractory to hypomethylating agents. Blood 2010; 116(21):1857
  • Lee HJ, Trump D, Johnson CS, Wang ES, Thompson JE, Griffiths EA, Vigil CE, Barcos M, Block A, Sait S, Ford LA, Wilding G, Wei T, Muindi J, Wetzler M. Subnormal vitamin D levels are associated with adverse outcome in newly-diagnosed similarly-treated adult acute myeloid leukemia (AML) patients. Blood 2010; 116(21):Abstract #1041
  • Metzeler KH, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Powell BL, Blum W, Wu Y, Maharry K, Radmacher MD, Mrozek K, Margeson D, Becker H, Curfman J, Holland KB, Schwind S, Whitman SP, Bloomfield CD . Mutations in the tet oncogene family member 2 (TET2) gene refine the new European LeukemiaNet risk classification of primary, cytogenetically normal acute myeloid leukemia (CN-AML) in adults: A cancer and leukemia group B (CALGB) study. Blood 2010; 116(21):98
  • Garcia-Manero G, Chiao JH, Strickland SA, Claxton D, Altman JK, Wetzler M, Maness LJ, Venugopal P, Luger SM, Kantarjian H. A randomized phase II study of sapacitabine in MDS refractory to hypomethylating agents. Journal of clinical oncology 2010; 28(15 Suppl.):6528
  • Lipton JH, Nanda N, Benichou A, Cram D, Masszi T, Baer MR, Baccarani M, Nicolini F, Wetzler M, Cortes JE. Safety of omacetaxine mepesuccinate (OM) subcutaneous (SQ) injection for the treatment of chronic myeloid leukemia (CML) patients (pts) resistant or intolerant to tyrosine kinase inhibitors (TKIs): Analysis of two phase II studies. Journal of clinical oncology 2010; 28(15 Suppl.):6568
  • Block AW, Thompson JE, Wang ES, Starostik P, Deeb G, Sait SN, Ford L, Wilding GE, Groman AE, Wetzler M. The role of FLT3 in sole trisomy 8 acute myeloid leukemia. Journal of clinical oncology 2010; 28(15 Suppl.):6562
  • Abutalib SA, Wetzler M, Stock W. Looking toward the future: novel strategies based on molecular pathogenesis of acute lymphoblastic leukemia. Hematology/oncology clinics of North America 2009; 23(5):1099-1119
  • Almyroudis NG, Fabian J, Hahn T, Segal BH, Wetzler M, McCarthy Jr PL. Late infectious complications after cord blood stem cell transplantation. European journal of clinical microbiology and infectious diseases 2009; 28(11):1405-1408
  • Benekli M, Baumann H, Wetzler M. Targeting signal transducer and activator of transcription signaling pathway in leukemias. Journal of clinical oncology 2009; 27(26):4422-4432
  • Cortes JE, Albitar M, McDougall K, Salvado A, Saleh M, Kerr R, Burke JM, Akard L, Wetzler M, Giles FJ, Powell BL, Goldberg SL, Kantarjian HM, Radich J. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. Journal of clinical oncology 2009; 27(28):4754-4759
  • Drake AS, Brady MT, Wang XH, Sait SJN, Earp JC, Ghoshal S, Ferrone S, Wang ES, Wetzler M. Targeting 11q23 positive acute leukemia cells with high molecular weight-melanoma associated antigen-specific monoclonal antibodies. Cancer immunology, immunotherapy : CII 2009; 58(3):415-427
  • Francis J, Loud P, Lamonica D, Syta M, Brown K, Paplham P, Bshara W, Barcos M, Wetzler M, Battiwalla M, Smiley S, McCarthy P. Detection of extra-medullary relapse of acute lymphoblastic leukemia by radiographic imaging following allogeneic hematopoietic SCT. Bone marrow transplantation 2009; 44(12):827-828
  • Harb A, Tan W, Wilding GE, Battiwalla M, Sait SNJ, Wang ES, Wetzler M. Acute myeloid leukemia and diabetes insipidus with monosomy 7. Cancer genetics and cytogenetics 2009; 190(2):97-100
  • Harb AJ, Wang ES, Wallace PK, Barcos M, Block AW, Sait SNJ, Ford L, Wilding GE, Tan W, Wetzler M. Treating octogenarian and nonagenarian acute myeloid leukemia patients--predictive prognostic models. Cancer 2009; 115(11):2472-2481
  • O'Brien S, Pinilla-Ibarz J, Radich JP, Shah NP, Shami PJ, Smith BD, Snyder DS, Tallman MS, Talpaz M, Mughal T, Moore JO, Berman E, Borghaei H, DeAngelo DJ, Devetten MP, Devine S, Erba HP, Gotlib J, Jagasia M, Wetzler M. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. Journal of the National Comprehensive Cancer Network : JNCCN 2009; 7(9):984-1023
  • Radich JP, Wetzler M, Sundar HM, Snyder DS, Smith BD, Houldsworth J, Horning SJ, Erba HP, Czuczman MS, Croce CM, Chan WC, Zelenetz AD, Winter JN. NCCN task force report: molecular markers in leukemias and lymphomas. Journal of the National Comprehensive Cancer Network : JNCCN 2009; 7 Suppl. 4:S1-S34, quiz S35-S36
  • Varadarajan R, Ford L, Sait SNJ, Block AW, Barcos M, Wallace PK, Ramnath N, Wang ES, Wetzler M. Metachronous and synchronous presentation of acute myeloid leukemia and lung cancer. Leukemia research 2009; 33(9):1208-1211
  • Wetzler M, Stock W. Preface: acute lymphoblastic leukemia--quo vadis?. Hematology/oncology clinics of North America 2009; 23(5):xi-xviii
  • Zeidan A, Wang ES, Wetzler M. Pegasparaginase: where do we stand?. Expert opinion on biological therapy 2009; 9(1):111-119
  • Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. Journal of clinical oncology 2011; 29(5):487-494
  • Wetzler M , Segal D. Omacetaxine as an Anticancer Therapeutic: What is Old is New Again. Current pharmaceutical design 2011; 17(1):59-64
  • Al Ustwani O, Francis J, Wallace PK, Ambrus J Jr, Wetzler M. Treating myelodysplastic syndrome improves an accompanying autoimmune disease along with a reduction in regulatory T-cells. Leukemia research 2011; 35(5):e35-e36
  • Almyroudis NG, Wetzler M, McCarthy PL Jr, Wang ES, Wongkittiroch K, Hazamy PA, Samonis G, Hahn T, Lesse AJ, Segal BH. Molecular epidemiology and risk factors for colonization by vancomycin-resistant Enterococcus in patients with hematologic malignancies. Infection control and hospital epidemiology 2011; 32(5):490-496
  • Deeb G, Vaughan MM, McInnis I, Ford LA, Sait SN, Starostik P, Wetzler M, Mashtare T, Wang ES. Hypoxia-inducible factor-1alpha protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia. Leukemia research 2011; 35(5):579-584
  • Lee HJ, Thompson JE, Wang ES, Wetzler M. Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives. Cancer 2011; 117(8):1583-1594
  • Metzeler KH, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Powell BL, Blum W, Wu YZ, Maharry K, Radmacher MD, Mrozek K, Margeson D, Becker H, Curfman J, Holland KB, Schwind S, Whitman SP, Bloomfield CD. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. Journal of clinical oncology 2011; 29(10):1373-1381
  • Noor SJ, Wang ES, Thompson JE, Block AW, Sait SN, Barcos M, Ford LA, Wilding GE, Tan W, Wetzler M. Myeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases. Leukemia research 2011; 35(5):608-613
  • Vigil C, Block AW, Wetzler M. The significance of quantifiable residual normal karyotype hematopoietic cells for toxicity and outcome. Leukemia and lymphoma 2011; 52(6):943
  • Vigil CE, Griffiths EA, Wang ES, Wetzler M. Interpretation of cytogenetic and molecular results in patients treated for CML. Blood reviews 2011; 25(3):139-146
  • Ghoshal Gupta S, Baumann H, Wetzler M. Epigenetic regulation of signal transducer and activator of transcription 3 in acute myeloid leukemia. Leukemia research 2008; 32(7):1005-1014
  • Shivakumar R, Tan W, Wilding GE, Wang ES, Wetzler M. Biologic features and treatment outcome of secondary acute lymphoblastic leukemia--a review of 101 cases. Annals of oncology 2008; 19(9):1634-1638
  • O'Brien S, Schilder RJ, Shami P, Smith BD, Snyder DS, Soiffer RJ, Tallman MS, Talpaz M, Wetzler M, Radich JP, Przepiorka D, Berman E, Bhalla K, Copelan EA, Devetten MP, Emanuel PD, Erba HP, Greenberg PL, Moore JO, National Comprehensive Cancer Network. Chronic myelogenous leukemia. Journal of the National Comprehensive Cancer Network : JNCCN 2007; 5(5):474-496
  • Tallman MS, Wetzler M, Rowe JM, Perez WS, Pedersen T, Mehta J, Litzow MR, Lazarus HM, Keating A, Logan BR, Gandham S, Dewald GW, Weisdorf DJ. Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission. Blood 2007; 110(1):409-417
  • Wetzler M, Earp JC, Brady MT, Keng MK, Jusko WJ. Synergism between arsenic trioxide and heat shock protein 90 inhibitors on signal transducer and activator of transcription protein 3 activity--pharmacodynamic drug-drug interaction modeling. Clinical cancer research 2007; 13(7):2261-2270
  • Wetzler M, Sanford BL, Kurtzberg J, DeOliveira D, Frankel SR, Powell BL, Kolitz JE, Bloomfield CD, Larson RA. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood 2007; 109(10):4164-4167
  • Zeidan A, Kakati S, Anderson B, Barcos M, Wetzler M. Monosomy 7 in t(9;22)-negative cells during nilotinib therapy in an imatinib-resistant chronic myeloid leukemia case. Cancer genetics and cytogenetics 2007; 176(2):169-171
  • Abdelhalim A, Barcos M, Block AW, Sait SN, Starostik P, Wetzler M, Wang ES. Remission of Philadelphia chromosome-positive central nervous system leukemia after dasatinib therapy. Leukemia and lymphoma 2007; 48(5):1053-1056
  • Wang ES, Wetzler M. Targeting CD40. Leukemia and lymphoma 2007; 48(2):229-231
  • Wetzler M, Donohue KA, Odenike OM, Feldman EJ, Hurd DD, Stone RM, Westerfelt P, Bloomfield CD, Larson RA. Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107. Leukemia and lymphoma 2008; 49(7):1274-1278
  • Zeidan A, Wang ES, Wetzler M. What is imatinib-resistant chronic myeloid leukemia? Identifying and managing loss of response. Clinical advances in hematology and oncology : H&O 2008; 6(9):673-683
  • Faderl S, Wetzler M, Rizzieri D, Schiller GJ, Jagasia MH, Stuart RK, Ganguly S, Avigan D, Craig M, Collins R, Maris MB, Kovacsovics T, Goldberg S, Seiter K, Hari P, Ravandi F, Wang ES, Eckert S, Huebner D, Kantarjian H. Clofarabine plus cytarabine compared to cytarabine alone in older patients with relapsed or refractory (R/R) acute myelogenous leukemia (AML): Results from the phase III CLASSIC 1 trial : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):6503
  • Vigil CE, Tan W, Wilding GE, Garcia-Manero G, Wang ES, Wetzler M, List AF. Comparison of outcome in erythroleukemia patients treated with standard chemotherapy regimens or hypomethylating agents : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):6630
  • Brady MT, Sait SNJ, Minderman H, Lee KP, Wetzler M. Knock-Down of Signal Transducer and Activator of Transcription 3 Enhances Acute Myeloid Leukemia-Derived Dendritic Cell Function. Blood 2009; 114(22):781
  • Cortes J, Paquette R, Talpaz M, Pinilla J, Asatiani E, Wetzler M, Lipton JH, Kasap C, Bui LA, Clary DO, Shah N. Preliminary Clinical Activity in a Phase I Trial of the BCR-ABL/IGF-1R/Aurora Kinase inhibitor XL228 in Patients with Ph+ Leukemias with Either Failure to Multiple TKI Therapies or with T3151 Mutation. Blood 2008; 112(11):1109-1110
  • Cortes J, Seiter K, Maziarz RT, Wetzler M, Craig M, Matous J, Luger S, Dey B, Schiller GJ, Pham D, Abboud CN, Krishnamurthy M, Brown A, Moore JO. Superiority of Rasburicase Versus Allopurinol on Serum Uric Acid Control in Adult Patients with Hematological Malignancies at Risk of Developing Tumor Lysis Syndrome: Results of a Randomized Comparative Phase III Study. Blood 2008; 112(11):340-341
  • Cortes-Franco J, Coutre S, Di Bona E, Lo-Coco F, Wetzler M, Sanz M, Wieland S, Barber JR, Kantarjian HM. A Phase II Study of Oral Tamibarotene in Acute Promyelocytic Leukemia (APL) Patients (PTS) Who Have Received Prior Therapy with All-Trans Retinoic Acid and Arsenic Trioxide (STAR-1 trial). Blood 2009; 114(22):809-810
  • Cortes-Franco J, Raghunadharao D, Parikh P, Wetzler M, Lipton JH, Jones D, Hochhaus A, Kantarjian HM, Craig AR, Benichou AC, Humphriss E, Nicolini FE. Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Chronic Myeloid Leukemia (CML) Patients Who Are Resistant or Intolerant to Two or More Tyrosine Kinase Inhibitors - Results of A Multicenter Phase 2/3 Study. Blood 2009; 114(22):354-355
  • Demock KM, Marinaro J, McInnis I, Ford LA, Wetzler M, Tian L, Deeb G, Wang ES. Hypoxia-Inducible Factor-1 Alpha (HIF-1 alpha) and HIF-2 alpha Are Independent Prognostic Factors for Normal Karyotype Acute Myeloid Leukemia (NK AML). Blood 2008; 112(11):887
  • Demock KM, Marinaro J, Sobczyk A, Ford LA, Wetzler M, Deeb G, Tian L, Wang ES. Expression of Vascular Endothelial Growth Factor Receptors VEGFR-1 and VEGFR-2 Are Prognostic Factors in Normal Karyotype Acute Myeloid Leukemia (NK-AML). Blood 2008; 112(11):886-887
  • Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M, Coutre S, Stock W, Borthakur G, Chiao J, Kantarjian H. A randomized phase II study of sapacitabine, an oral nucleoside analogue, in elderly patients with AML previously untreated or in first relapse or previously treated MDS. Journal of clinical oncology 2009; 27(15 Suppl.):Abstract #7021
  • Garcia-Manero G, Luger S, Venugopal P, Maness LJ, Wetzler M, Altman J, Claxton DF, Strickland S, Faderl S, Chiao J, Kantarjian HM. A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, in Older Patients with Myelodysplastic Syndrome (MDS) Refractory to Hypomethylating Agents. Blood 2009; 114(22):698-699
  • Gupta G, Rao I, Jusko WJ, Wetzler M. The effect of arsenic trioxide against signal transducer and activator of transcription protein 3 in acute myeloid leukemia is independent of heat shock protein 70-pharmacodynamic drug-drug interaction modeling. Proceedings of the American Association for Cancer Research Annual Meeting 2009; 50:879
  • Kantarjian HM, Garcia-Manero G, Luger S, Venugopal P, Maness LJ, Wetzler M, Stock W, Coutre S, Borthakur G, Chiao J. A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, in Elderly Patients with AML Previously Untreated or in First Relapse. Blood 2009; 114(22):438
  • Kuptsova-Clarkson N, Ambrosone C, Weiss J, Baer MR, Sucheston L, Zirpoli G, Kopecky K, Ford LA, Blanco J, Wetzler M, Moysich K. XPD DNA Nucleotide Excision Repair (NER) Gene Polymorphisms Associated with DNA Repair Deficiency May Predict Better Treatment Outcomes in Secondary Acute Myeloid Leukemia (AML). Blood 2009; 114(22):75
  • Lancet JE, Gotlib J, Wetzler M, Luger S, Cripe LD, Tallman MS, Gojo I, Mulford D, Baer MR, List AF, Multani PS, Sikic BI. Phase I/II study of the P-glycoprotein (Pgp) inhibitor zosuquidar administered by continuous infusion (CIV) with daunorubicin (DNR) and cytarabine (ARA-C) as primary therapy in older patients with Pgp-positive acute myeloid leukemia (AML). Blood 2007; 110(11 Part 1):Abstract #299
  • McInnis I, Hahn T, Ioane A, Larnson A, Lal D, Ford LA, Sait SNJ, Starostik P, Deeb G, Wetzler M, Mashtare T, Wang ES. Diverse Roles of Hepatocyte Growth Factor (HGF) in Normal Karyotype Acute Myeloid Leukemia (AML). Blood 2009; 114(22):1208
  • Noor S, Tan W, Wilding G, Ford LA, Barcos M, Sait SNJ, Block AW, Thompson JE, Wang ES, Wetzler M. Myeloid Blastic Transformation of Myeloproliferative Neoplasms - A Review of 113 Cases. Blood 2009; 114(22):1210
  • Shivakumar R, Tan W, Wilding G, Wang ES, Wetzler M. Biologic features and treatment outcome of secondary acute lymphoblastic leukemia - Review of 101 cases. Blood 2007; 110(11 Part 2):154B (Abstract #4345)
  • Stock W, Sanford B, Lozanski G, Vij R, Byrd JC, Powell BL, Wetzler M, Sher D, Edwards C, Kelly M, Richards S, Sung C, Malnassy G, Hoke E, Bloomfield CD, Larson RA. Alemtuzumab can be Incorporated Into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102). Blood 2009; 114(22):345
  • Varadarajan R, Licht A, Hyland AJ, Ford LA, Barcos M, Sait SNJ, Block AW, Baer MR, Thompson JE, Wang ES, Wetzler M. Smoking Adversely Affects Survival in Acute Myeloid Leukemia Patients. Blood 2009; 114(22):407
  • Wang ES, Sobczyk A, Marinaro JM, Wetzler M, Tian L, Deeb G. VEGF-A, VEGF-C, and CD31 expression by leukemia cells are prognostic factors for overall survival in acute myeloid leukemia (AML). Blood 2007; 110(11 Part 1):Abstract #2392
  • Wetzler M, Hellmann A, Lipton J, Roy L, Jones D, Schenk T, Hochhaus A, Benichou A, Kantarjian H, Cortes J. Subcutaneous omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients resistant or intolerant to two or more tyrosine kinase inhibitors (TKIs): Data from an ongoing phase II trial. Journal of clinical oncology 2009; 27(15 Suppl.):Abstract #7027
  • Wetzler M, Stock W, Linker C, Larson RA. Imatinib and autologous stem cell transplantation for Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL) - CALGB study 10001. Annals of hematology 2008; 87(Suppl. 1):S92-S94
  • Zeidan A, Gaile D, Conroy JM, McQuaid DE, Wang ES, Deeb G, Wallace PK, Sait SNJ, Nowak NJ, Wetzler M. Frequent molecular aberrations in normal karyotype (NC) precursor B-cell acute lymphoblastic leukemia (pB-ALL) detected by comparative genomic hybridization. Blood 2007; 110(11 Part 2):135B (Abstract #4270)
  • Zeidan A, Tan W, Wilding G, Ford L, Hahn T, Smiley S, Battiwalla M, McCarthy PL, Wang ES, Wetzler M. Gemtuzumab Ozogamicin (GO) and Continuous Infusion Cytarabine (ARA-C) for Relapsed/Refractory Acute Myeloid Leukemia (AML) Prior to Allogeneic Stem Cell Transplantation (SCT). Blood 2008; 112(11):350-351
  • Lee HJ, Wright KM, Kandeel E, Tan W, Wilding GE, Ford LA, Sait SN, Block AMW, Barcos MP, McCarthy PL, Vigil CE, Griffiths EA, Thompson JE, Wang ES, Wallace PK, Wetzler M. The role of minimal residual disease (MRD) by flow cytometry (FC) in predicting outcome in similarly treated acute lymphoblastic leukemia (ALL) patients : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):6592
  • Smonskey M, Starostik P, Deeb G, Demock K, Vargas R, Lal D, Sait SN, Wetzler M, Wang ES. Association of IDH1 mutations in normal karyotype acute myeloid leukemia samples with higher HIF-1{alpha} and VEGF-A expression : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):6530
  • Stone RM, Allen SL, Pigneux A, Stuart RK, Wetzler M, Rizzieri D, Erba HP, Damon LE, Jang JH, Tallman MS, Warzocha K, Masszi T, Sekeres MA, Miklos E, Horst H, Selleslag DLD, Solomon SR, Venugopal P, Lundberg AS, Powell BL. A phase III, open-label, randomized comparison of AS1413 (amonafide L-malate) plus cytarabine with daunorubicin plus cytarabine in secondary acute myeloid leukemia (ACCEDE) : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):6520
  • Becker H, Maharry K, Radmacher MD, Mrozek K, Metzeler KH, Whitman SP, Schwind S, Kohlschmidt J, Wu Y-Z, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Moore JO, Caligiuri MA, Larson RA, Marcucci G, Bloomfield CD. Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Haematologica 2011; 96(10):1488-1495
  • Wetzler M, Andrews C, Ford LA, Tighe S, Barcos M, Sait SN, Block AW, Nowak NJ, Baer MR, Wang ES, Baumann H. Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia. Cancer 2011; 117(21):4861-4868
  • Cortes J, Kantarjian H, Ball ED, DiPersio J, Kolitz JE, Fernandez HF, Goodman M, Borthakur G, Baer MR, Wetzler M. Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cancer 2012; 118(2):418-427
  • Cortes JE, Nicolini FE, Wetzler M, Lipton JH, Akard LP, Craig A, Nanda N, Dial C, Benichou AC, Cairati K, Baccarani M, Kennealey GT, Kantarjian HM. Subcutaneous Omacetaxine in Chronic or Accelerated Chronic Myeloid Leukemia Resistant to Two or More Tyrosine-Kinase Inhibitors Including Imatinib. Blood 2011; 118(21):1605-1606
  • Eisfeld AK, Marcucci G, Maharry K, Schwind S, Radmacher MD, Nicolet D, Becker H, Whitman SP, Metzeler KH, Mrozek K, Wu YZ, Baer MR, Powell BL, Carter TH, Moore JO, Kolitz JE, Wetzler M, Caligiuri MA, Larson RA, Tanner SM, de la Chapelle A, Bloomfield CD. MiR-3151, a Novel MicroRNA Embedded in BAALC, Is Only Weakly Co-Expressed with Its Host Gene and Independently Impacts on the Clinical Outcome of Older Patients (Pts) with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML). Blood 2011; 118(21):635
  • Ganguly S, Kantarjian HM, Wetzler M, Rizzieri D, Schiller G, Hagasia M, Stuart R, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Golberg S, Seiter K, Hari P, Greiner J, Vey N, Recher C, Ravandi F, Wang E, Eckert S, Partisano A, Faderl S. Subsequent Hematopoietic Stem Cell Transplantation (HSCT) Associated with Longer Survival in Patients with Relapsed/Refractory (R/R) Acute Myelogenous Leukemia (AML) After Clo+Ara-C or Ara-C Alone: A Landmark Analysis from the Classic I Trial. Biology of blood and marrow transplantation 2012; 18(2 Suppl.):S211-S212
  • Ghoshal S, Brady MT, Ustwani O, Tracy E, Den Haese J, Wallace PK, Baumann H, Wetzler M. Signal Transducer and Activator of Transcription 3 Promotes Leukemogenesis. Blood 2011; 118(21):609
  • Griffiths EA, Karpf AR, Odunsi K, James SR, Beck AF, Wetzler M, Ford LA. Conventional Dose Hypomethylating Agents Induce CG Antigen Genes In Vivo. Blood 2011; 118(21):1049
  • Lee HJ, Licht AS, Hyland AJ, Ford LA, Sait SN, Block AW, Barcos M, Baer MR, Wang ES, Wetzler M. Is obesity a prognostic factor for acute myeloid leukemia outcome?. Annals of hematology 2012; 91(3):359-365
  • Liu H, Zhang YL, Hahn T, Thomas J, Wetzler M, Wang ES, Hernandez L, Ross M, Chen GL, McCarthy PL. Optimizing the Timing of Allogeneic Blood or Marrow Transplantation (BMT) in a Prospective Cohort of Relapsed or Refractory Acute Myeloid Leukemia (AML). Blood 2011; 118(21):1338
  • Marcucci G, Metzeler KH, Schwind S, Becker H, Maharry K, Mrozek K, Radmacher MD, Kohlschmidt J, Nicolet D, Whitman SP, Wu Y-Z, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Moore JO, Caligiuri MA, Larson RA, Bloomfield CD. Age-Related Prognostic Impact of Different Types of DNMT3A Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia. Journal of clinical oncology 2012; 30(7):742-750
  • Mendler JH, Maharry K, Radmacher MD, Mrozek K, Kohlschmidt J, Nicolet D, Becker H, Metzeler KH, Schwind S, Whitman SP, Blum W, Powell BL, Kolitz JE, Carter TH, Wetzler M, Moore JO, Carroll AJ, Baer MR, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD. Poor Outcome of RUNX1-Mutated (RUNX1-mut) Patients (Pts) with Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) and Associated Gene- and MicroRNA (miR) Expression Signatures. Blood 2011; 118(21):1476-1477
  • Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, Mrozek K, Nicolet D, Whitman SP, Wu YZ, Schwind S, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD. ASXL1 Mutations Identify a High-Risk Subgroup of Older Patients with Primary Cytogenetically Normal Acute Myeloid Leukemia within the European LeukemiaNet 'Favorable' Genetic Category. Blood 2011; 118(21):192
  • Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, Mrozek K, Nicolet D, Whitman SP, Wu Y-Z, Schwind S, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood 2011; 118(26):6920-6929
  • O'Brien S, Abboud CN, Akhtari M, Altman J, Berman E, DeAngelo DJ, Devine S, Fathi AT, Gotlib J, Jagasia M, Moore JO, Pinilla-Ibarz J, Radich JP, Reddy VVB, Shah NP, Shami PJ, Smith BD, Snyder DS, Wetzler M, Yunus F. Chronic myelogenous leukemia. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network : JNCCN 2012; 10(1):64-110
  • Ravandi F, Faderl S, Cortes JE, Garcia-Manero G, Jabbour E, Boone PA, Kadia T, Borthakur G, Wierda WG, Wetzler M, Venugopal P, Chiao J, Kantarjian HM. Phase 1/2 Study of Sapacitabine and Decitabine Administered Sequentially in Elderly Patients with Newly Diagnosed AML. Blood 2011; 118(21):1550-1551
  • Reddy PL, Choppa P, Moradian MM, Potter NT, Quigley MM, Watt CD, Hofling H, Manning B, Mignault A, Mullaney B, Ossa D, Stein A, Wang SS, Yang F, Wetzler M. Evaluation of MMR Concordance Based on Either International Scale (IS) or National Comprehensive Cancer Network (NCCN) Criteria Using Reconstructed "Virtual" CML Patient Profiles From the REVEAL BCR-ABL Methods Comparison Study. Blood 2011; 118(21):1511-1512
  • Rondelli D, Goldberg JD, Marchioli R, Isola L, Shore TB, Prchal JT, Bacigalupo A, Rambaldi A, Klisovic RB, Gupta V, Andreasson B, Demakos EP, Price LS, Scarano M, Wetzler M, Vannucchi AM, Najfeld V, Barosi G, Silverman LR, Hoffman R. Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis. Blood 2011; 118(21):763
  • Varadarajan R, Licht AS, Hyland AJ, Ford LA, Sait SNJ, Block AW, Barcos M, Baer MR, Wang ES, Wetzler M. Smoking adversely affects survival in acute myeloid leukemia patients. International journal of cancer 2012; 130(6):1451-1458
  • Wetzler M, Kohlschmidt J, Mrozek K, Dombret H, Dohner H, Pilorge S, Krug U, Larson RA, Marcucci G, Hiddemann W, Buchner T, Bloomfield CD. Prognostic Significance of Karyotype in Octogenarian Patients (Pts) with Acute Myeloid Leukemia (AML)-An International Study. Blood 2011; 118(21):1080-1081
  • Jarkowski A 3rd, Forrest A, Sweeney RP, Tan W, Segal BH, Almyroudis N, Wang ES, Wetzler M. Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population. Journal of oncology pharmacy practice 2012; 18(1):91-96
  • Thudium KE, Haese JD, Karpf A, Fetterly G, Wetzler M. Synergistic effects of clofarabine and decitabine in acute myeloid leukemia. Proceedings of the American Association for Cancer Research Annual Meeting 2011; 52:Abstract #5380
  • Damodaran S, Bellavia T, Sait SNJ, Wang ES, Wetzler M, Khushalani NI. Acute myeloid leukemia secondary to oxaliplatin treatment for esophageal cancer. Clinical colorectal cancer 2012; 11(2):151-154
  • Akard LP, Kantarjian H, Nicolini FE, Wetzler M, Lipton JH, Baccarani M, Craig A, Nanda N, Brown PD, Cortes JE. Omacetaxine mepesuccinate in chronic-phase chronic myeloid leukemia (CML) in patients resistant, intolerant, or both to two or more tyrosine-kinase inhibitors (TKIs). Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #6596
  • Garcia-Manero G, Luger SM, Goldberg S, Altman JK, Arellano ML, Wetzler M, Seiter K, Chiao JH, Kantarjian H. A randomized phase II study of sapacitabine in MDS refractory to hypomethylating agents. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #6520
  • Nicolini FE, Lipton JH, Kantarjian H, Wetzler M, Akard LP, Baccarani M, Craig A, Nanda N, Brown PD, Cortes JE. Subcutaneous omacetaxine mepesuccinate in patients with chronic phase (CP) or accelerated phase (AP) chronic myeloid leukemia (CML) resistant/intolerant to two or three approved tyrosine-kinase inhibitors (TKIs). Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #6513
  • Vigil CE, Griffiths EA, Thompson JE, Tan W, Greene J, Ford LA, Wang ES, Wetzler M. A phase II study of clofarabine and daunorubicin in patients age 60 or older with newly diagnosed adult acute myeloid leukemia. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #6602
  • Wetzler M, Kantarjian H, Nicolini FE, Lipton JH, Akard LP, Baccarani M, Craig A, Brown PD, Cortes JE. Pooled safety analysis of omacetaxine mepesuccinate in patients with chronic myeloid leukemia (CML) resistant to tyrosine-kinase inhibitors (TKIs). Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #6604
  • Cortes J, Wetzler M, Akard L, Lipton JH, Benichou AC, Craig AR, Humphriss E, Kantarjian H. Multicenter open label study of subcutaneous (SC) omacetaxine (OMA) in chronic myeloid leukemia (CML) patients (Pts) that are resistant or intolerant to two or more tyrosine kinase inhibitors (TKIS). Haematologica 2008; 93(Suppl. 1):0546
  • Wetzler M, Parikh PM, Raghunadharao D, Jones D, Leitner A, Hochhaus A, Benichou AC, Craig AR, Humphriss E, Kantarjian H, Cortes J. Multicenter open label study of subcutaneous (SC) omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients that are resistant or intolerant to two or more tyrosine kinase inhibitors (TKIS). Haematologica 2009; 94(Suppl. 2):192-193 (Abstract #0477)
  • Sardesai SD, Tan W, Ford LA, Deeb G, Block AMW, Sait SNJ, McCarthy PL, Vigil CE, Griffiths EA, Thompson JE, Wang ES, Wallace PK, Wetzler M. Predicting outcome based on minimal residual disease (MRD) using multiparameter flow cytometry (FC) in acute myeloid leukemia (AML) patients (Pts) : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #6565
  • Eisfeld A-K, Marcucci G, Maharry K, Schwind S, Radmacher MD, Nicolet D, Becker H, Mrozek K, Whitman SP, Metzeler KH, Mendler JH, Wu Y-Z, Liyanarachchi S, Patel R, Baer MR, Powell BL, Carter TH, Moore JO, Kolitz JE, Wetzler M, Caligiuri MA, Larson RA, Tanner SM, De La Chapelle A, Bloomfield CD. miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. Blood 2012; 120(2):249-258
  • Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Goldberg S, Seiter K, Hari P, Greiner J, Vey N, Recher C, Ravandi F, Wang ES, Vasconcelles M, Huebner D, Kantarjian HM. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. Journal of clinical oncology 2012; 30(20):2492-2499
  • Mendler JH, Maharry K, Radmacher MD, Mrozek K, Becker H, Metzeler KH, Schwind S, Whitman SP, Khalife J, Kohlschmidt J, Nicolet D, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD . RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and microRNA expression signatures. Journal of clinical oncology 2012; 30(25):3109-3118
  • Thudium KE, Ghoshal S, Fetterly GJ, Haese JP, Karpf AR, Wetzler M. Synergism between clofarabine and decitabine through p53R2: A pharmacodynamic drug-drug interaction modeling. Leukemia research 2012; 36(11):1410-1416
  • Alvarnas JC, Brown PA, Aoun P, Ballen KK, Bellam N, Blum W, Boyer MW, Carraway HE, Coccia PF, Coutre SE, Cultrera J, Damon LE, DeAngelo DJ, Douer D, Frangoul H, Frankfurt O, Goorha S, Millenson MM, O'Brien S, Petersdorf SH, Rao AV, Terezakis S, Uy G, Wetzler M, Zelenetz AD, Naganuma M, Gregory KM. Acute lymphoblastic leukemia. Journal of the National Comprehensive Cancer Network : JNCCN 2012; 10(7):858-914
  • Wang ES, Zeidan A, Tan W, Wilding GE, Ford LA, Wallace PK, Hahn TE, Battiwalla M, McCarthy PL, Wetzler M. Cytoreduction with gemtuzumab ozogamicin and cytarabine prior to allogeneic stem cell transplant for relapsed/refractory acute myeloid leukemia. Leukemia and lymphoma 2012; 53(10):2085-2088
  • Whitman SP, Caligiuri MA, Maharry K, Radmacher MD, Kohlschmidt J, Becker H, Mrozek K, Wu Y-Z, Schwind S, Metzeler KH, Mendler JH, Wen J, Baer MR, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Larson RA, Marcucci G, Bloomfield CD. The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia. Leukemia 2012; 26(7):1713-1717
Referral
Email: 
Meir.Wetzler@RoswellPark.org
Fax: 
716-845-2343
Source URL (retrieved on 05/23/2013 - 9:59am): http://www.roswellpark.org/meir-wetzler